DK1507529T3 - Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid - Google Patents

Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid

Info

Publication number
DK1507529T3
DK1507529T3 DK03732397T DK03732397T DK1507529T3 DK 1507529 T3 DK1507529 T3 DK 1507529T3 DK 03732397 T DK03732397 T DK 03732397T DK 03732397 T DK03732397 T DK 03732397T DK 1507529 T3 DK1507529 T3 DK 1507529T3
Authority
DK
Denmark
Prior art keywords
hydrochlorothiazide
amlodipine
combination containing
containing valsartan
valsartan
Prior art date
Application number
DK03732397T
Other languages
Danish (da)
English (en)
Inventor
Suraj Shivappa Shetty
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1507529(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1507529T3 publication Critical patent/DK1507529T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
DK03732397T 2002-05-17 2003-05-16 Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid DK1507529T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38154702P 2002-05-17 2002-05-17
PCT/EP2003/005180 WO2003097045A1 (en) 2002-05-17 2003-05-16 Combination of organic compounds

Publications (1)

Publication Number Publication Date
DK1507529T3 true DK1507529T3 (da) 2009-08-03

Family

ID=29550142

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03732397T DK1507529T3 (da) 2002-05-17 2003-05-16 Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid

Country Status (29)

Country Link
US (3) US20050222137A1 (enExample)
EP (1) EP1507529B8 (enExample)
JP (2) JP5132872B2 (enExample)
KR (2) KR20050000546A (enExample)
CN (2) CN1652777A (enExample)
AR (1) AR040014A1 (enExample)
AT (1) ATE429223T1 (enExample)
AU (1) AU2003240261B2 (enExample)
BR (1) BR0310092A (enExample)
CA (1) CA2486144C (enExample)
CY (1) CY1109240T1 (enExample)
DE (1) DE60327316D1 (enExample)
DK (1) DK1507529T3 (enExample)
EC (1) ECSP045429A (enExample)
EG (1) EG24716A (enExample)
ES (1) ES2325207T3 (enExample)
IL (1) IL164925A (enExample)
MX (1) MXPA04011385A (enExample)
MY (1) MY138838A (enExample)
NO (1) NO333011B1 (enExample)
NZ (1) NZ536557A (enExample)
PE (1) PE20040439A1 (enExample)
PL (1) PL372369A1 (enExample)
PT (1) PT1507529E (enExample)
RU (1) RU2324482C2 (enExample)
SI (1) SI1507529T1 (enExample)
TW (1) TWI358291B (enExample)
WO (1) WO2003097045A1 (enExample)
ZA (1) ZA200408737B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RS20050590A (sr) * 2003-01-31 2007-09-21 Sankyo Company Limited, Lek za profilaksu i tretman arterioskleroze i hipertenzije
CN100444840C (zh) 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
CA2525665A1 (en) * 2003-05-16 2004-11-25 Novartis Ag Pharmaceutical composition comprising valsartan
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
ATE451925T1 (de) * 2004-10-06 2010-01-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung
AU2005300787B2 (en) * 2004-11-05 2011-05-26 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
CN1830454A (zh) * 2005-03-10 2006-09-13 刘智仁 盐酸在制备治疗高血压药物中的应用
EP1872783B1 (en) * 2005-04-21 2011-12-28 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal/conjunctival disorder
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
KR101384841B1 (ko) * 2005-06-27 2014-04-15 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를함유한 약학 제제
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AU2007234380A1 (en) * 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
AR061627A1 (es) * 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
GB2471970A (en) * 2006-09-15 2011-01-19 Daiichi Sankyo Co Ltd Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
CN101199848B (zh) * 2006-11-11 2012-05-23 深圳奥萨医药有限公司 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途
PT2106260T (pt) 2007-01-25 2018-03-05 Naia Metabolic Inc Sensibilizadores de insulina e métodos de tratamento
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
BRPI0817516A2 (pt) 2007-10-05 2015-06-16 Alzheimer S Inst Of America Inc Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino
US8785432B2 (en) * 2007-12-31 2014-07-22 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2010085014A1 (en) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
RU2398581C1 (ru) * 2009-05-28 2010-09-10 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) Способ лечения больных гипертрофической кардиомиопатией
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
RU2425671C1 (ru) * 2010-06-30 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции нарушений функции почек у больных стабильной стенокардией в сочетании с гипертонической болезнью
TR201102067A1 (tr) 2011-03-03 2012-09-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan ve amlodipin kombinasyonları.
GB201116993D0 (en) 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
MX2014013320A (es) 2012-05-07 2015-08-10 Bayer Pharma AG Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo.
WO2013191668A1 (en) 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
US10918612B2 (en) * 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
ES2847904T3 (es) 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
CN104324377B (zh) * 2014-06-19 2017-08-04 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
KR101914930B1 (ko) * 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
KR20180123021A (ko) * 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 신질환의 치료를 위한 의약
US10319209B2 (en) 2016-06-03 2019-06-11 John Carlton-Foss Method and system for motion analysis and fall prevention
KR20180053044A (ko) * 2016-11-11 2018-05-21 주식회사유한양행 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
FI3573620T3 (fi) 2017-01-25 2023-03-25 The George Inst For Global Health Koostumuksia kohonneen verenpaineen hoitamiseksi
JP7223701B2 (ja) 2017-02-27 2023-02-16 イドーシア ファーマシューティカルズ リミテッド ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤
MA51203A (fr) 2017-11-30 2020-10-07 Idorsia Pharmaceuticals Ltd Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
MX2021001043A (es) * 2018-07-26 2021-04-12 The George Inst For Global Health Composiciones para el tratamiento de hipertension.
CN111789843A (zh) 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης
KR20240014345A (ko) 2022-07-25 2024-02-01 안국약품 주식회사 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
US5449682A (en) 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
JP3398379B2 (ja) 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5492904A (en) 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5260325A (en) 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5206348A (en) 1992-07-23 1993-04-27 Morton International, Inc. Hexahydroxybenzophenone sulfonate esters of diazonaphthoquinone sensitizers and positive photoresists employing same
US5264447A (en) 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5266583A (en) 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
ES2243933T3 (es) 1994-02-08 2005-12-01 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
FI963611A0 (fi) 1994-03-17 1996-09-13 Ciba Geigy Ag Diabeettisen munuaissairauden hoito valsartaanilla
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
BR9708336A (pt) 1996-03-29 1999-08-03 Smithkline Beecham Corp Diidrato de eprosartan e processo para sua produção e formulação
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5949290A (en) * 1997-01-14 1999-09-07 Bertram; Earnest L. Voltage controlled oscillator tuning apparatus and method
WO1998046270A2 (en) 1997-04-11 1998-10-22 Advanced Medicine, Inc. Polymeric conjugates polyvalently presenting an agent for therapy
US5991348A (en) * 1997-08-12 1999-11-23 3Com Corporation Method and apparatus for regenerating symbol timing from a probing signal in a system having non-linear network and codec distortion
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
SI1096932T1 (sl) * 1998-07-10 2008-04-30 Novartis Pharma Ag Antihipertenzivna kombinacija valsartana in zaviralca kalcijevih kanalov
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
ES2281978T3 (es) 1998-12-23 2007-10-01 Novartis Ag Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2.
KR100674053B1 (ko) 1999-01-26 2007-01-25 노파르티스 아게 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
CN1301545A (zh) 1999-12-27 2001-07-04 王德山 一种复方降血压药
DE10004651A1 (de) * 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
AU8967201A (en) 2000-07-19 2002-01-30 Novartis Ag Valsartan salts
CA2430924A1 (en) 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas

Also Published As

Publication number Publication date
US20120115854A1 (en) 2012-05-10
PT1507529E (pt) 2009-07-24
WO2003097045A1 (en) 2003-11-27
AR040014A1 (es) 2005-03-09
CA2486144A1 (en) 2003-11-27
JP5132872B2 (ja) 2013-01-30
CY1109240T1 (el) 2014-07-02
ATE429223T1 (de) 2009-05-15
KR20050000546A (ko) 2005-01-05
PL372369A1 (en) 2005-07-25
ES2325207T3 (es) 2009-08-28
KR101454070B1 (ko) 2014-10-23
RU2004137105A (ru) 2005-09-10
TW200406204A (en) 2004-05-01
NO333011B1 (no) 2013-02-18
US20050222137A1 (en) 2005-10-06
NZ536557A (en) 2006-10-27
EG24716A (en) 2010-06-07
RU2324482C2 (ru) 2008-05-20
MXPA04011385A (es) 2005-02-14
US8101599B2 (en) 2012-01-24
MY138838A (en) 2009-07-31
CA2486144C (en) 2012-02-07
ZA200408737B (en) 2006-02-22
HK1074773A1 (en) 2005-11-25
EP1507529A1 (en) 2005-02-23
US20090099241A1 (en) 2009-04-16
BR0310092A (pt) 2005-02-15
NO20045429L (no) 2004-12-13
TWI358291B (en) 2012-02-21
DE60327316D1 (de) 2009-06-04
PE20040439A1 (es) 2004-08-20
IL164925A (en) 2014-04-30
ECSP045429A (es) 2005-01-03
EP1507529B8 (en) 2010-02-24
KR20110107877A (ko) 2011-10-04
AU2003240261A1 (en) 2003-12-02
AU2003240261B2 (en) 2007-06-28
EP1507529B1 (en) 2009-04-22
JP2005533023A (ja) 2005-11-04
JP2010209123A (ja) 2010-09-24
SI1507529T1 (sl) 2009-10-31
CN101890166A (zh) 2010-11-24
IL164925A0 (en) 2005-12-18
CN1652777A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
DK1507529T3 (da) Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid
DK1814527T4 (da) Dobbeltlagstablet omfattende telmisartan og amlodipin
IS8803A (is) Efnasambönd, sem innihalda laktam og afleiður þeirra sem tálmar Xa þáttar
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
DE60237997D1 (de) Sicherheitsanordnung
GB0202734D0 (en) Personal alarm device
NO20044662L (no) Forbindelser, blandinger og fremgangsmater
AU2003284001A8 (en) Triazolone and triazolethione derivatives
DK1556013T3 (da) Dispergerbare deferasirox-tabletter
DE60310069D1 (de) Netzwerksicherheit
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20043279L (no) Kombinasjoner som innbefatter epotiloner og antimetabolitter
IS7783A (is) Flóð og fjöru-ker
IS7694A (is) Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
NL1023684A1 (nl) Tweebladig metselwerk en verbindingselement daarvoor.
FR2845718B1 (fr) Serrure et huisserie correspondante
IS8182A (is) Díarýlmetýlídenpíperídínafleiður, blöndur og notkun þeirra
NO20055142D0 (no) Diarylmetylidenpiperidinderivater, fremstillinger og anvendelser derav
FI5464U1 (fi) Amlodipiini
ATA19142002A (de) Sicherheitsdokument
GB0221769D0 (en) Portable security alarm
GB0229563D0 (en) Sheeting without drilling
GB0224648D0 (en) Personal alarm
ITMI20020581A1 (it) Barriera anti-intrusione